Accuracy in Space and Time: Diagnosing Multiple Sclerosis Genzyme Corporation, a Sanofi company.

Size: px
Start display at page:

Download "Accuracy in Space and Time: Diagnosing Multiple Sclerosis. 2012 Genzyme Corporation, a Sanofi company."

Transcription

1 Accuracy in Space and Time: Diagnosing Multiple Sclerosis 2012 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by MS.US.PO your gateway to MS knowledge. Brought to you by Powered by your gateway to MS knowledge. 1

2 Epidemiology Multiple Sclerosis Multiple sclerosis is a chronic, unpredictable disease of the central nervous system (the brain, optic nerves, and spinal cord) Affects more than 400,000 in the US and 2.1 million worldwide More than twice as common in women as in men Most people are diagnosed between the ages of 20 and 50, although individuals as young as 2 and as old as 75 have developed it Powered by 2

3 Typical symptoms Symptoms of MS are unpredictable and can vary from person to person, and from time to time in the same person Symptoms may include partial or complete paralysis; difficulties with vision, cognition, speech and elimination; fatigue; sensory changes; difficulty walking; slurred speech; tremors; stiffness; bladder dysfunction Sometimes major symptoms disappear completely and a patient may regain lost function In severe MS, people have symptoms on a permanent basis Powered by 3

4 Clinical disease starts with a clinically isolated syndrome Powered by 4

5 Making the diagnosis of MS can be challenging Difficult diagnostic groups Monosymptomatic presentation Insidious neurologic progression (primary progressive MS) Explosive onset Vague symptoms Delays in accurate diagnosis could mean loss of crucial time in a disease with a limited treatment window. Powered by 5

6 What s the first step to effective treatment? Powered by 6

7 Diagnostic principles 1. Dissemination in space (DIS) 2. Dissemination in time (DIT) 3. Rule out mimics Powered by 7

8 Differential diagnosis Powered by 8

9 Red flags for the misdiagnosis of MS History and physical Normal neurologic examination Abnormality in a single location (no DIS) Progressive from onset (no DIT) Onset in childhood or over age 50 Systemic disease present Prominent family history (consider genetic disease) Gray matter symptoms: dementia, seizures, aphasia Peripheral symptoms: neuropathy, fasciculations Acute hemiparesis Lack of typical symptoms (no optic neuritis, bladder problems, Lhermitte sign, etc) Prolonged benign course (eg, diagnosis made years ago with few findings now) Tests Normal or atypical MRI Normal cerebrospinal fluid (CSF) Abnormal blood tests (though many are false positives) Powered by 9

10 MRI mimics: Which is which? Powered by 10

11 MRI alone is NOT specific for MS Powered by 11

12 Evolution of diagnostic criteria: Early history Powered by 12

13 1965 Schumacher criteria Clinically definite multiple sclerosis 1. Objective signs of dysfunction of the central nervous system; symptoms not acceptable 2. Evidence of damage to 2 or more sites 3. Predominantly damage to the white matter 4a. Two or more episodes of at least 24 hours separated by at least 6 months 4b. Slow or stepwise progression over 6 months 5. Age of onset years 6. Diagnosis by a neurologist; signs and symptoms cannot be explained by other disease No pathognomonic laboratory test for MS useful in selecting cases has been discovered. Powered by 13

14 1982 Poser criteria Note: Paraclinical evidence defined as evoked potentials, CT or MRI; at least two oligoclonal bands, none in serum. Powered by 14

15 McDonald criteria *May include findings on neurological examination, visual evoked response in patients reporting prior visual disturbance, or MRI consistent with demyelination in the implicated area of the CNS. Can include historical events with symptoms and evolution characteristics of a prior inflammatory demyelinating event. Powered by 15

16 2010 McDonald MRI criteria: Definition of attack A patient-reported or objectively observed event, current or historical, with duration of at least 24 hours in the absence of fever or infection It should be supported by findings on neurological examination Reports of paroxysmal symptoms (historical or current) should consist of multiple episodes occurring over not less than 24 hours Before a definite diagnosis of MS can be made, at least 1 attack must be corroborated by Findings on neurological examination Visual evoked potential response in patients reporting prior visual disturbance MRI consistent with demyelination in the area of the CNS implicated in the historical report of neurological symptoms Powered by 16

17 2010 McDonald MRI criteria: Demonstration of DIS Powered by 17

18 2010 McDonald MRI criteria: Demonstration of DIT Powered by 18

19 2010 McDonald criteria: PPMS Powered by 19

20 CSF no longer part of McDonald criteria for MS According to the 2001 and 2005 McDonald criteria: A positive CSF finding could be used to reduce the MRI requirements for reaching DIS criteria (requiring only 2 or more MRI-detected lesions consistent with MS if the CSF was positive) In 2010: Because imaging criteria for DIS and DIT were simplified, the panel believed further liberalizing MRI requirements in CSF-positive patients was not appropriate, and CSF was removed from the criteria for MS The panel reaffirmed that positive CSF findings can be important to support the inflammatory demyelinating nature of the underlying condition, to evaluate alternative diagnoses, and to predict CDMS Powered by 20

21 Review of McDonald updates from 2001 to 2011 MRI DIT Powered by 21

22 McDonald criteria: Accuracy for predicting future CDMS 1 year after patients presented with CIS, McDonald criteria (2001) were applied: Sensitivity: 83% Specificity: 83% Positive predictive value: 75% Negative predictive value: 89% Many more patients were identified by McDonald (2001) vs Poser Percentage of patients diagnosed with MS 1 year after initially presenting with CIS was 48% using McDonald criteria vs 20% using Poser criteria Powered by 22

23 Prognosis remains a major challenge The most reliable prognostic factors are: Frequency and characteristics of relapses early in disease Occurrence of a progressive phase Characteristics of disease onset associated with better prognosis Monosymptomatic Optic neuritis Complete recovery Long time interval between first and second relapse Lower number of relapses in initial years Powered by 23

24 Risk factors associated with future disability Age at onset ( 40 vs >40 years) Symptoms at onset (isolated sensory/cranial nerve vs motor or motor + sensory) MRI status (Negative vs suspicious vs suggestive) Interval between 1st and 2nd attack ( 2.5 years vs <2.5 years) Attack frequency in 1st 2 years of study ( 2 vs >2) Completeness of recovery from initial attacks (Good vs poor) Powered by 24

25 Future directions MRI techniques Powered by 25

26 Future directions Potential biomarkers Genomics Human leukocyte antigen (HLA) Immune mediators Cytokines Chemokines Activation markers Adhesion molecules Pathogens Epstein-Barr Human herpesvirus 6 MS-associated retrovirus Powered by 26

27 References Dalton CM, Brex PA, Miszkiel KA, et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol. 2002;52: De Stefano N, Battaglini M, Stromillo ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain. 2006;129: Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Mag Res Imag. 2010;31: Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J. 2005;81: McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50: National Multiple Sclerosis Society. Just the facts. NMMS Web site. Accessed June 5, Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol. 2011;69: Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria. Ann Neurol. 2005;58: Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg. 2004;106: Powered by 27

28 References Rolak LA, Fleming JO. The differential diagnosis of multiple sclerosis. The Neurologist. 2007;13: Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurology. 2000;55: Shaw C, Chapman C, Butzkueven H. How to diagnose multiple sclerosis and what are the pitfalls. Intern Med J. 2009;39: Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain. 2005;128: Traboulsee A, Li DKB. Conventional MR imaging. Neuroimag Clin N Am. 2008;18: Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist. 1999;5: Villoslada P. Biomarkers for multiple sclerosis. Drug News Perspect. 2010;23: Vukusic S, Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol. 2007;20: Powered by 28

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents

More information

Trauma Insurance Claims Seminar Invitation

Trauma Insurance Claims Seminar Invitation Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims

More information

Clinical features. Chapter 2. Clinical manifestations. Course

Clinical features. Chapter 2. Clinical manifestations. Course Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent

More information

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for

More information

AUBAGIO (teriflunomide) oral tablet

AUBAGIO (teriflunomide) oral tablet AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Clinically isolated syndrome (CIS)

Clinically isolated syndrome (CIS) Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would

More information

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare Immunomodulatory Therapies in Pediatric MS Vuong Chinh Quyen Neurology Department Medscape Mar 8, 2013 Multiple Sclerosis in Children. Iran J Child Neurol. 2013 Spring Introduction acquired chronic immune-mediated

More information

A Definition of Multiple Sclerosis

A Definition of Multiple Sclerosis English 182 READING PRACTICE by Alyx Meltzer, Spring 2009 Vocabulary Preview (see bolded, underlined words) gait: (n) a particular way of walking transient: (adj) temporary; synonym = transitory remission:

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

More information

Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role

Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals

More information

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004. Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the

More information

CNS DEMYLINATING DISORDERS

CNS DEMYLINATING DISORDERS CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such

More information

What is Multiple Sclerosis? Gener al information

What is Multiple Sclerosis? Gener al information What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal

More information

2.1 Who first described NMO?

2.1 Who first described NMO? History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first

More information

Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València

Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València Rational basis for early treatment in MS Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València Bonaventura Casanova Department of Neurology University Hospital La

More information

Summary chapter 2 chapter 2

Summary chapter 2 chapter 2 Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological

More information

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute The Impact of Multiple Sclerosis in the Pacific Northwest James Bowen, MD Multiple Sclerosis Center Multiple Sclerosis Center Swedish Neuroscience Institute 1 2 Motor Symptoms of MS Weakness Spasticity

More information

Multiple Sclerosis. Matt Hulvey BL A - 615

Multiple Sclerosis. Matt Hulvey BL A - 615 Multiple Sclerosis Matt Hulvey BL A - 615 Multiple Sclerosis Multiple Sclerosis (MS) is an idiopathic inflammatory disease of the central nervous system (CNS) MS is characterized by demyelination (lesions)

More information

Coping with Symptoms of Multiple Sclerosis

Coping with Symptoms of Multiple Sclerosis Coping with Symptoms of Multiple Sclerosis Josée Poirier B. Sc. Nursing, MSCN Outline What Is a Pseudo exacerbation? Awareness Advancement of Treatments Treatment of Symptoms Uhthoff s Phenomenon What

More information

Natural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d

Natural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d Natural history of multiple sclerosis: risk factors and prognostic indicators Sandra Vukusic a,b,c,d and Christian Confavreux a,b,c,d Purpose of review To highlight progress in the description of the natural

More information

43. MULTIPLE SCLEROSIS

43. MULTIPLE SCLEROSIS Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System, as agreed by the Interterritorial Board 43. MULTIPLE

More information

Chapter 2 Diagnosis CONTENTS

Chapter 2 Diagnosis CONTENTS Chapter 2 Diagnosis CONTENTS 2.1 Introduction----------------------------------------------------------------------------------------- 3 2.2 Overview----------------------------------------------------------------------------------------------

More information

AUBMC Multiple Sclerosis Center

AUBMC Multiple Sclerosis Center AUBMC Multiple Sclerosis Center 1 AUBMC Multiple Sclerosis Center The vision of the American University of Beirut Medical Center (AUBMC) is to be the leading academic medical center in Lebanon and the

More information

MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author

MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author MULTIPLE SCLEROSIS Mary Beth Rensberger, RN, BSN, MPH Author All rights reserved. Purchasers of this module are permitted to reproduce the forms contained herein for their individual internal use only.

More information

Reversibility of Acute Demyelinating Lesions in relapsingremitting

Reversibility of Acute Demyelinating Lesions in relapsingremitting Reversibility of Acute Demyelinating Lesions in relapsingremitting Multiple Sclerosis Omar A. Khan ( Division of Neuroimmunology, Department of Neurology, Neurology and Research Services. Veterans Affairs

More information

Update: MRI in Multiple sclerosis

Update: MRI in Multiple sclerosis Nyt indenfor MS ved MR Update: MRI in Multiple sclerosis Hartwig Roman Siebner Danish Research Centre for Magnetic Resonance (DRCMR) Copenhagen University Hospital Hvidovre Dansk Radiologisk Selskabs 10.

More information

MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY

MULTIPLE SCLEROSIS. Megan Snyder INTRODUCTION TO EPIDEMOLOGY MULTIPLE SCLEROSIS Megan Snyder INTRODUCTION TO EPIDEMOLOGY Snyder 1 Personal Connection to Multiple Sclerosis Multiple sclerosis (MS) is an extremely painful disease of which not enough is understood.

More information

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain. Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around

More information

About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?

About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common? An introduction to multiple sclerosis for people who have recently been diagnosed When you have just been diagnosed with multiple sclerosis, you will probably have many questions about the condition and

More information

How To Use A Drug In Multiple Sclerosis

How To Use A Drug In Multiple Sclerosis Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and

More information

CBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area

CBT IN THE CITY. adjusted to the news of being with MS? April 2013. Experts at your fingertips call now. Check out our new services in you local area April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the

More information

CLINICALLY ISOLATED SYNDROME

CLINICALLY ISOLATED SYNDROME CLINICALLY ISOLATED SYNDROME: WHY TO TREAT? * Jacquelyn Bainbridge, PharmD ABSTRACT Clinically isolated syndrome (CIS) is the first symptomatic neurologic episode consistent with multiple sclerosis (MS).

More information

What is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter

What is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted

More information

Clinical Trials of Disease Modifying Treatments

Clinical Trials of Disease Modifying Treatments MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,

More information

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS

More information

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment Understanding your Tecfidera treatment Information for patients who have been prescribed treatment with Tecfidera. (dimethyl fumarate) Contents About Multiple Sclerosis (MS) What is MS? Symptoms of MS

More information

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY

THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY THE NATURAL HISTORY OF MS: DIAGNOSIS, CLINICAL COURSE, AND EPIDEMIOLOGY John R. Rinker II, MD University of Alabama at Birmingham Birmingham VA Medical Center May 29, 2014 DISCLOSURES Salary/Research:

More information

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Relapsing-remitting multiple sclerosis Ambulatory with or without aid AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date

More information

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program

More information

Disclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.

Disclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS. Disclosure Statement Multiple Sclerosis: Current Trends in Treatment Member of Speaker s Bureau Biogen Idec Will discuss non FDA approved therapies Christine St Laurent MSN, RN, MSCN 19 th Annual Mud Season

More information

Multiple Sclerosis & MS Ireland Media Fact Sheet

Multiple Sclerosis & MS Ireland Media Fact Sheet Multiple Sclerosis & MS Ireland Media Fact Sheet This fact sheets gives a summary of the main facts and issues relating to Multiple Sclerosis and gives an overview of the services offered by MS Ireland.

More information

Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy

Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza, Egypt

More information

Progress in the field: therapeutic improvements for all patients?

Progress in the field: therapeutic improvements for all patients? Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination

More information

OHTAC Recommendation

OHTAC Recommendation OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the

More information

Multiple Sclerosis: What You Need To Know. For Professionals

Multiple Sclerosis: What You Need To Know. For Professionals Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought

More information

MRI in Differential Diagnosis

MRI in Differential Diagnosis MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards

More information

Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI

Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI Background information Progressive multifocal leukoencephalopathy (PML) PML is a demyelinating disease that attacks the

More information

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON First-line DMTs Reduce Relapse Frequency by ~30% vs. Placebo Frequency of relapse with various DMTs, based

More information

Using the MS Clinical Course Descriptions in Clinical Practice

Using the MS Clinical Course Descriptions in Clinical Practice Using the MS Clinical Course Descriptions in Clinical Practice Mark J. Tullman, MD Director of Clinical Research The MS Center for Innovations in Care Missouri Baptist Medical Center Disclosures Consultant/speaking

More information

Multiple sclerosis (MS)

Multiple sclerosis (MS) Multiple sclerosis (MS) Summary Multiple sclerosis (MS) is an incurable disease of the central nervous system that can affect the brain, spinal cord and optic nerves. The effects of MS are varied and unpredictable,

More information

Multiple Sclerosis: An imaging review and update on new treatments.

Multiple Sclerosis: An imaging review and update on new treatments. Multiple Sclerosis: An imaging review and update on new treatments. Dr Marcus Likeman Consultant Neuroradiologist North Bristol NHS Trust Bristol Royal Hospital for Children MRI appearances - White Matter

More information

MULTIPLE SCLEROSIS 2015. Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine

MULTIPLE SCLEROSIS 2015. Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine MULTIPLE SCLEROSIS 2015 Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine Disclosure Research support, Sunovion and Marinus for epilepsy research Goals and Objectives

More information

Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com

Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management CME University, FreeCME.com, Powerpak.com Faculty Clyde E. Markowitz, MD Associate Professor of Neurology Director, Multiple

More information

Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner

Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner Managing the Symptoms of Multiple Sclerosis Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner What is Multiple Sclerosis An autoimmune disease that affects the central nervous system (CNS) The immune

More information

Homework 5: Differential Diagnosis of Multiple Sclerosis

Homework 5: Differential Diagnosis of Multiple Sclerosis Homework 5: Differential Diagnosis of Multiple Sclerosis Due Wednesday, 3/3/99 1.0 Background Multiple Sclerosis affects approximately 350 K Americans and is the leading nontraumatic source of neurologic

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 343 N OVEMBER 16, 2 NUMBER 2 RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS CHRISTIAN CONFAVREUX,

More information

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012. Reference : NHSCB/D4/c/1 Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December 2012 Reference : NHSCB/D4/c/1 NHS Commissioning Board Clinical Commissioning Policy: Disease

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 15 September 2005 Doc. Ref. EMEA/CHMP/EWP/561/98 Rev 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

More information

Suspected cases of multiple sclerosis (MS) are usually young adults attending the neurology

Suspected cases of multiple sclerosis (MS) are usually young adults attending the neurology J Neurol Neurosurg Psychiatry 2001;71(suppl II):ii3 ii8 MAKING THE DIAGNOSIS OF MULTIPLE SCLEROSIS J Palace *ii3 Suspected cases of multiple sclerosis (MS) are usually young adults attending the neurology

More information

Advanced Multiple Sclerosis: Progressive MS Epidemiology

Advanced Multiple Sclerosis: Progressive MS Epidemiology Advanced Multiple Sclerosis: Progressive MS Epidemiology CMSC 2007-Washington, DC Mitchell T. Wallin, MD, MPH Associate Director-Clinical Care VA MS Center of Excellence-East East Associate Professor of

More information

Key issues in the diagnosis and treatment of multiple sclerosis

Key issues in the diagnosis and treatment of multiple sclerosis Neurology 2002;59:S1-S33 2002 American Academy of Neurology Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not

More information

Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis

Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis Taylor Slotte Pathology Disease Report Spring 2014 Multiple Sclerosis Abstract Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the body s central nervous system. It affects the brain,

More information

Life with MS: Striving for Maximal Independence & Fulfillment

Life with MS: Striving for Maximal Independence & Fulfillment Life with MS: Striving for Maximal Independence & Fulfillment St. Louis, May 7, 2005 Florian P. Thomas, MA, MD, PhD MS Center, Department of Neurology Associate Professor, Saint Louis University Brain

More information

Choices Primary Progressive MS (PPMS)

Choices Primary Progressive MS (PPMS) Choices Primary Progressive MS (PPMS) What is primary progressive MS? Approximately 10% of people with MS worldwide are told they have primary progressive MS a form of MS where from the very first symptoms,

More information

Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate.

Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. What is Multiple Sclerosis? Multiple Sclerosis (MS) is a disease of the central nervous system (including the brain and spinal cord) in which the nerves degenerate. A disease of the central nervous system

More information

MS Treatments Aubagio TM

MS Treatments Aubagio TM 1 MSology Essentials Series Aubagio TM (teriflunomide) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Bonnie Blain Central Alberta MS Clinic, Red Deer, Alberta

More information

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

A blood sample will be collected annually for up to 2 years for JCV antibody testing. Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:

More information

Natalizumab (Tysabri)

Natalizumab (Tysabri) Natalizumab (Tysabri) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Natalizumab (Tysabri) Date of issue: July 2010 Review date: July 2011 Contents Section

More information

Primary progressive MS exposed. Alison Whittam

Primary progressive MS exposed. Alison Whittam Primary progressive MS exposed Alison Whittam Primary progressive MS exposed Alison Whittam, Information Officer, MS Trust The MS Trust is a UK charity for people with MS, their family and friends. The

More information

Chapter 10. Summary & Future perspectives

Chapter 10. Summary & Future perspectives Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency London, 16 November 2006 Doc. Ref. CPMP/EWP/561/98 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS FOR THE

More information

Multifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD

Multifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD Multifocal Motor Neuropathy Jonathan Katz, MD Richard Lewis, MD What is Multifocal Motor Neuropathy? Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by

More information

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

More information

PROPOSED REVISIONS TO THE CRITERIA. multiple sclerosis (RRMS)] Chapter 6 6 It is recognised that use is in only exceptional circumstances in RRMS.

PROPOSED REVISIONS TO THE CRITERIA. multiple sclerosis (RRMS)] Chapter 6 6 It is recognised that use is in only exceptional circumstances in RRMS. Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM Condition Name Multiple Sclerosis (MS) Multiple

More information

Acute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD

Acute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD Acute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD Acute demyelinating optic neuritis associated with multiple sclerosis (MS) is

More information

The Clinical Characteristics of Optic Neuritis in Korean Children

The Clinical Characteristics of Optic Neuritis in Korean Children pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2011;25(2):116-120 DOI: 10.3341/kjo.2011.25.2.116 The Clinical Characteristics of Optic Neuritis in Korean Children Original Article Dong Hyun Jo 1,2,

More information

Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis SPECIAL REPORT Recommended Diagnostic Criteria f Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis W. Ian McDonald, FRCP, 1 Alistair Compston, FRCP, 2 Gilles

More information

Multiple sclerosis. Great Ormond Street Hospital for Children NHS Foundation Trust: Information for young people. What is Multiple Sclerosis?

Multiple sclerosis. Great Ormond Street Hospital for Children NHS Foundation Trust: Information for young people. What is Multiple Sclerosis? Great Ormond Street Hospital for Children NHS Foundation Trust: Information for young people Multiple sclerosis When young people are told that they have a diagnosis of Multiple Sclerosis (MS) they usually

More information

A Letter From the MS Coalition

A Letter From the MS Coalition 0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding

More information

Natalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY

Natalizumab (Tysabri) and PMLthe current figures. Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Natalizumab (Tysabri) and PMLthe current figures Paul-Ehrlich-Institut Brigitte Keller Stanislawski Paul-Ehrlich-Str. 51-59 63225 Langen GERMANY Humanised MAB Natalizumab Specific binding to a4-integrin

More information

NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso

NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso Introduction Multiple sclerosis (MS), in its many and varied clinical forms,

More information

Life with MS: Mastering Early Treatment

Life with MS: Mastering Early Treatment Life with MS: Mastering Early Treatment Essential Information About MS Multiple sclerosis (MS) is a disease that attacks the central nervous system (CNS). Approximately 2.5 million people worldwide and

More information

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case

More information

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors 148 J Neurol Neurosurg Psychiatry 1999;67:148 152 Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors S A Hawkins, G V McDonnell Northern Ireland Regional

More information

Use of imaging in multiple sclerosis

Use of imaging in multiple sclerosis CHAPTER 3 Use of imaging in multiple sclerosis M. Filippi, 1 M. A. Rocca, 1 D. L. Arnold,2 R. Bakshi,3 F. B ar khof, 4 5 N. De Stefano, F. Fazekas,6 E. Frohman,7 D. H. Mil le r, 8 9 J. S. Wolinsky 1 Institute

More information

Multiple Sclerosis Jeffrey M. Gelfand, MD

Multiple Sclerosis Jeffrey M. Gelfand, MD Multiple Sclerosis Jeffrey M. Gelfand, MD UCSF Multiple Sclerosis Center SFGH Neuroimmunology Clinic UCSF and SFGH Departments of Neurology Goals To review the fundamentals of neurological localization

More information

CAMBRIDGE UNIVERSITY CENTRE FOR BRAIN REPAIR A layman's account of our scientific objectives What is Brain Damage? Many forms of trauma and disease affect the nervous system to produce permanent neurological

More information

Headache: Differential diagnosis and Evaluation. Raymond Rios PGY-1 Pediatrics

Headache: Differential diagnosis and Evaluation. Raymond Rios PGY-1 Pediatrics Headache: Differential diagnosis and Evaluation Raymond Rios PGY-1 Pediatrics You are evaluating a 9 year old male patient at the ED brought by his mother, who says that her son has had a fever, cough,

More information

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families Understanding Relapse in Multiple Sclerosis A guide for people with MS and their families Introduction You have been given this booklet because you have been diagnosed with Multiple Sclerosis (MS) and

More information

The Burden of Disease

The Burden of Disease The Burden of Disease A closer look at the consequences of living with multiple sclerosis 2011 Genzyme Corporation, a Sanofi company. Brought All rights to reserved. you by www.msatrium.com, MS.US.PO83.0711E

More information

Progress in MS: Current and Emerging Therapies

Progress in MS: Current and Emerging Therapies Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC The MS Society gratefully acknowledges the grant received from Biogen Idec Canada, which makes possible the

More information

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January

More information

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011

Conflict of Interest Declaration. Overview of New Medications for Multiple Sclerosis. Assessment Question. Objectives 4/1/2011 Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

More information

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre Managing Relapsing Remitting MS Risks & benefits of emerging therapies Dr Mike Boggild The Walton Centre MS: Facts and figures Affects 1 in 800 in the UK Commonest cause of acquired neurological disability

More information

Treatment Optimization in MS: When to Start, When to Shift, when to Stop

Treatment Optimization in MS: When to Start, When to Shift, when to Stop Treatment Optimization in MS: When to Start, When to Shift, when to Stop Mark S. Freedman MSc MD FAAN FANA FRCPC Director, Multiple Sclerosis Research Unit University of Ottawa Sr. Scientist, Ottawa Hospital

More information

Natalizumab and the Risk of PML

Natalizumab and the Risk of PML Natalizumab and the Risk of PML Gloria von Geldern, MD Multiple Sclerosis Center Assistant Professor of Neurology University of Washington May 13, 2015 Conflict of Interest Dr. von Geldern has nothing

More information

1: Motor neurone disease (MND)

1: Motor neurone disease (MND) 1: Motor neurone disease (MND) This section provides basic facts about motor neurone disease (MND) and its diagnosis. The following information is an extracted section from our full guide Living with motor

More information

The Evolution of In Vivo Confocal Microscopy for Quantitative Corneal Imaging W. Matthew Petroll, Ph.D.

The Evolution of In Vivo Confocal Microscopy for Quantitative Corneal Imaging W. Matthew Petroll, Ph.D. Genetics in Eye Disease: From Discovery to Clinical Applications Lucia Sobrin, MD, MPH I. Introduction a. Mendelian Genetic Diseases i. Sequencing b. Complex Polygenic Diseases i. Genome-wide association

More information

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician

What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making

More information

Voting for your top research questions Survey

Voting for your top research questions Survey MS Priority Setting Partnership Voting for your top research questions Survey Prioritising important research questions for multiple sclerosis a partnership between people affected by MS and healthcare

More information